The Eversense PASS™ Program offers savings on THE ONLY long-term CGM System with 6 months of real-time glucose readings.
To help eligible people with diabetes more affordably access the Eversense E3 CGM System†
$99 for 6 months
Eligible individuals can experience EVERSENSE E3 CGM for only $99, now and in the future.†
That includes the patient’s initial and ongoing sensor and sensor/transmitter combinations – which is
equivalent to an average monthly cost of $16.50!
If you're on insulin, you might greatly benefit from Eversense. Whether you’re ready to get started now or just have additional questions about Eversense, an Ascensia Diabetes Care (Ascensia) representative can help. Fill in and submit the form below and we’ll be in touch via phone or text. We’ll also send you additional information about Eversense to help with your decision.
All fields marked with an asterisk (*) are required.
A Diabetes Therapy Associate will be in touch shortly, but if you want to reach out sooner, please call 1-945-221-9068.
To help expedite benefits verification, please have your doctor and insurance information handy.
We will attempt to reach you by phone first, and will send a text and email as well. The call may be displayed on your phone as "Eversense CGM". However, it will come from a number you are unfamiliar with, so be sure to check your voicemail box. The email from our representative will come from an @ascensia.com email address. If you haven’t received any email communications from our team within a few days, please check the spam folder in your email account.
Unfortunately, based on the insulin therapy regimen or insurance information you provided, you may not be eligible for Eversense E3 CGM. In order to qualify, you must be on multiple daily doses of insulin.
If your commercial insurance plan does not cover Eversense E3 CGM, our Eversense PASS™ program may help reduce your out-of-pocket cost for the product. .
If you have any questions, please reach out to 1-844-736-7348.
† Offer does not apply to the insertion and removal procedures. The Eversense PASS Program has limitations on eligibility.
See website (bit.ly/EversensePass) for more details. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which out-of-pocket costs exceed what is detailed in the offer.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For safety information click here.
Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.


Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.